GRAIL, Inc. announced integration of its Galleri Test into the Epic electronic health record platform, marking a significant advance for early cancer detection nationwide. This integration will enable clinicians across approximately 450 health systems to order and view Galleri Test results within their existing clinical workflows, greatly improving operational efficiency and enhancing patient care experiences.
The Galleri Test, a blood-based multi-cancer early detection tool, can screen for more than 50 types of cancer before symptoms arise, offering clinicians a powerful complement to traditional screening methods. By embedding the Galleri Test directly into the Epic system, GRAIL is working to remove administrative barriers and expand access to early cancer detection across the United States.
Under this collaboration, clinicians using the Epic EHR system will have the ability to order Galleri Tests right from their point-of-care station and view the results immediately, which will be a more streamlined process for the clinician. Additionally, the implementation of this process aims to minimize some of the manual tasks that usually delay patient experiences.
“Today, recommended screening exists for only five cancers in the U.S., yet more than 70% of deaths are caused by cancers without a recommended screening test,” said Josh Ofman, President at GRAIL, highlighting the urgent need for broader detection solutions. He emphasized that the Epic integration will help clinicians incorporate the Galleri Test into routine care, supporting early detection when treatment outcomes may be most favorable.
Implementation planning began in the first quarter of 2026, and early adopter programs are already underway. GRAIL will collaborate with Epic, its cloud partner AWS, and healthcare systems to ensure smooth deployment, training, and workflow alignment. The company expects broad availability of the integrated solution by the end of 2026.
Epic Aura, the framework enabling this integration, is widely used by large health systems across the country. By incorporating the Galleri Test into Epic Aura, GRAIL and Epic aim to support clinicians with a scalable, user-friendly solution that can be adopted within routine clinical care and patient engagement channels.
Healthcare administrators and clinicians have noted the practical benefits of having Galleri Test data accessible directly within the electronic health record. Philip Oravetz, Chief Population Health Officer at Ochsner Health, explained that embedding the Galleri Test within the Epic infrastructure reduces administrative burdens and allows for more efficient patient identification and test ordering.
Indeed, seamless electronic integration supports proactive, population-focused health care approaches. It enables clinicians to access test results within their established workflows, helping to avoid duplication of effort and enhancing the overall clinician experience. Moreover, centralized test results within patient records can facilitate better follow-up coordination and long-term patient management.
The Galleri Test itself requires a prescription from a licensed healthcare provider and is recommended for adults with an elevated risk of cancer, such as those aged 50 or older. It is intended to be used in addition to recommended screening tools such as mammography or colonoscopy. The test’s ability to detect a signal for many cancer types before symptoms appear positions it as a potential game-changer in early cancer detection efforts.
Although the Galleri Test is not yet cleared or approved by the U.S. Food and Drug Administration, it operates under CLIA regulations and has demonstrated promising performance in clinical use. Importantly, the test also provides a cancer signal of origin, aiding clinicians in guiding efficient diagnostic work-ups when a signal is detected.
Both patient advocates and health care professionals have expressed their appreciation for this innovation since early diagnosis of any form of cancer can greatly increase survival chances while lowering the cost of treating such a disease at an advanced stage.
The integration is anticipated to spread to more health care facilities in the coming months as more health practitioners undergo training and make use of the Galleri test in their clinical practice. Considering that cancer is still one of the major killers in many parts of the world, the introduction of early detection programs represents a critical step forward in population health care efforts.
Healthcare systems interested in adopting the Galleri Test through Epic’s EHR can learn more on the official Galleri website, where GRAIL provides resources tailored for health systems and clinicians.
